Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study

Table 2

Patients’ demographics and clinical variables in the longitudinal study.

	AP + AP	AP	𝑃	Effect size	df
Age (years)	44.9 ± 10.2	48.2 ± 13.5	0.38		40
Gender m/f	9/12	13/8	0.35		1
Age at onset (years)	24.1 ± 9.4	29.6 ± 13.5	0.19		29
Duration of disease (years)	21.1 ± 7.4	21.1 ± 12.1	0.97		29
Diagnosis 𝑛 (%)
(i) Schizophrenia	9	17	0.1		3
(ii) Schizoaffective	1	1
(iii) Bipolar disorder type I	6	2
(iv) Bipolar disorder NOS	4	1
Comorbid diagnosis (𝑛):
(i) Mental retardation	2	2	0.15		3
(ii) Cognitive impairment	0	2
(iii) Alcoholism	5	3
(iv) Personality disorder	0	1
Psychotropic drugs 𝑛 (%)
(i) First generation antipsychotics	21*	1	0.002	𝑥: 16.04	4
(ii) Second generation antipsychotics	24	14
(iii) Mood stabilizers	15	18
(iv) Antidepressants	2	2
(v) Benzodiazepines	8	9
(vi) Anticholinergics	1	2
Antipsychotic doses (in mg/day chlorpromazine equivalents)	920.57 ± 400.09*	450.66 ± 250.41	0.0001	𝑡: 4.31	40

Here, we reported data on (i) demographics in AP + AP versus AP patients included in the longitudinal study; (ii) rates and distribution of psychiatric and organic comorbid diagnoses in AP + AP versus AP patients; (iii) rates and distribution of antipsychotic and non-antipsychotic psychotropic agents in AP + AP versus AP patients; (iv) antipsychotic doses (in mean mg/day chlorpromazine equivalents) in AP + AP versus AP patients. Demographic and pharmacological variables were compared by Student’s 𝑡 test. Diagnosis and antipsychotic distribution were compared by chi-square test. Significant values have been marked in bold and with an asterisk and given with effect size (𝑡, 𝑥). df: degrees of freedom.